Aquestive Therapeutics (AQST) Debt to Equity (2017 - 2025)
Historic Debt to Equity for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to -$8.83.
- Aquestive Therapeutics' Debt to Equity fell 118169.19% to -$8.83 in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.83, marking a year-over-year decrease of 118169.19%. This contributed to the annual value of -$0.54 for FY2024, which is 10914.24% down from last year.
- Latest data reveals that Aquestive Therapeutics reported Debt to Equity of -$8.83 as of Q3 2025, which was down 118169.19% from -$0.48 recorded in Q2 2025.
- Over the past 5 years, Aquestive Therapeutics' Debt to Equity peaked at -$0.26 during Q4 2023, and registered a low of -$8.83 during Q3 2025.
- For the 5-year period, Aquestive Therapeutics' Debt to Equity averaged around -$1.0, with its median value being -$0.56 (2022).
- In the last 5 years, Aquestive Therapeutics' Debt to Equity skyrocketed by 7488.09% in 2021 and then crashed by 118169.19% in 2025.
- Over the past 5 years, Aquestive Therapeutics' Debt to Equity (Quarter) stood at -$0.65 in 2021, then skyrocketed by 32.57% to -$0.44 in 2022, then skyrocketed by 41.23% to -$0.26 in 2023, then crashed by 109.14% to -$0.54 in 2024, then tumbled by 1532.39% to -$8.83 in 2025.
- Its Debt to Equity stands at -$8.83 for Q3 2025, versus -$0.48 for Q2 2025 and -$0.55 for Q1 2025.